MS Treatment Shifts Toward Repair | Dubai News

A breakthrough in MS treatment is on the horizon with Lucid-MS, the first drug designed to repair damaged myelin rather than just suppress the immune system. Approved for Phase 2 trials by the FDA, it signals a major shift toward fixing nerve damage itself — though experts stress this is early-stage research and not a cure. Patients should view it as a hopeful addition to current therapies, not an immediate solution. Meanwhile, the UAE is emerging as a key player in MS research, thanks to strong local infrastructure and increased funding from the National Multiple Sclerosis Society — helping to address historical underrepresentation of the region in global health studies, especially since MS disproportionately affects younger women there. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/63cd2e1066d83eda